Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment.

A. Bjerrum (Århus, Denmark), S. Tina (Århus, Denmark), S. Johannes Martin (Århus, Denmark)

Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Session: Advances in asthma treatment: monoclonal antibodies
Session type: E-poster
Number: 3732

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Bjerrum (Århus, Denmark), S. Tina (Århus, Denmark), S. Johannes Martin (Århus, Denmark). Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment.. 3732

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018
Year: 2019



One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 618s
Year: 2004

First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020




Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008


Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


Patient-reported side effects of oral corticosteroids
Source: International Congress 2018 – Medical education via the web and the internet
Year: 2018

Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016



Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003


Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018


Therapeutic effects of topical calcilytic in IgE/Th2 and alarmin-driven surrogates of human asthma
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019



Long-term treatment of aspirin-intolerante asthma with budesonide. Effectivity and safety
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma
Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019
Year: 2020



Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD
Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018
Year: 2019